Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Quidel Corporation to Attend the Sixth Annual Craig-Hallum Institutional Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Jun. 10, 2009-- Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced that it will attend the Sixth Annual Craig-Hallum Institutional Investor Conference to be held at the Radisson Plaza Hotel in Minneapolis, Minnesota on June 11, 2009.

Doug Bryant, president and chief executive officer, and John Radak, chief financial officer, will participate in group and individual meetings with institutional investors. To accommodate investors unable to attend the conference the Company’s investor relations presentation will be available beginning on June 11, 2009 at www.quidel.com under the “Presentations” section found within the Investor Relations portion of the site.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com or www.flutest.com.

Source: Quidel Corporation

Quidel Corporation
John M. Radak, Chief Financial Officer, 858-646-8032
or
Porter Novelli Life Sciences
Parag Dave, 619-849-5378
pdave@pnlifesciences.com